VIR - Vir Biotechnology Inc. (VIR) Q1 2024 Earnings Call Transcript

2024-05-03 00:35:24 ET

Vir Biotechnology, Inc. (VIR)

Q1 2024 Earnings Conference Call

May 02, 2024, 04:30 PM ET

Company Participants

Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer

Marianne De Backer - Chief Executive Officer

Carrie Huang - Senior Vice President, Clinical Research and Interim Chief Medical Officer

Sung Lee - Chief Financial Officer

Conference Call Participants

Gena Wang - Barclays

Paul Choi - Goldman Sachs

Alec Stranahan - Bank of America

Phil Nadeau - TD Cowen

Patrick Trucchio - H.C. Wainwright

Rosa Chen - Leerink Partners

Joseph Stringer - Needham & Company

Eric Joseph - JP Morgan

Michaels Ulz - Morgan Stanley

Presentation

Operator

Hello. Welcome to Vir Biotechnology’s First Quarter 2024 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session.

I will now turn the call over to Sasha Damouni Ellis, Executive Vice President, Chief Corporate Affairs Officer. You may begin, Ms. Damouni Ellis.

Sasha Damouni Ellis

Thank you, and good afternoon. With me today are Dr. Marianne De Backer, Chief Executive Officer; Dr. Carrie Huang, Senior Vice President, Clinical Research and Interim Chief Medical Officer; and Sung Lee, Executive Vice President and Chief Financial Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements, to differ significantly from those expressed or implied by such forward looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including forms 10-K, 10-Q and 8-K....

For further details see: